With fewer biopharma companies performing all of their manufacturing in-house, CDMOs provide much-needed, at-scale production capacity, as well as outsourced services such as drug development and testing to reduce costs and tap outside expertise.
The company’s cash deal, which is expected to be completed by the end of 2025, secures purification and filtration technologies used in the production of biologics.
The collaboration aims to enhance clinical timelines and streamline production by leveraging Cellex’s expertise in cell and gene therapy manufacturing.
If the FDA’s decision stands, compounders will have a grace period before the agency enforces rules that would put an end to their making off-brand copies of the drugs.
